Information Provided By:
Fly News Breaks for March 4, 2020
LIFE
Mar 4, 2020 | 08:07 EDT
Roth Capital analyst Zegbeh Jallah initiated coverage of aTyr Pharma with a Buy rating and $15 price target. The analyst cited "strong" scientific data for the company's lead candidate, ATYR1923, a tRNA synthetase-derived drug for Pulmonary Sarcoidosis an interstitial lung disease for which efficacy data is expected during Q3; '1923's potential to capture share in the larger ILD market; and collaborations with CSL-Behring and Kyorin that provide further platform validation and non-dilutive capital.
News For LIFE From the Last 2 Days
There are no results for your query LIFE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.